Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 10:53:37 27/06/2024 pm IST			5-day change	1st Jan Change
3.295 ^USD	+2.33%		+2.33%	-74.54%

15/05	Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Windtree Therapeutics Seeks Acquisitions	CI

Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 16, 2024 at 02:30 am IST

Windtree Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net income was USD 10.22 million compared to net loss of USD 4.11 million a year ago. Basic earnings per share from continuing operations was USD 21.98 compared to basic loss per share from continuing operations of USD 85.65 a year ago.

Latest news about Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Windtree Therapeutics Seeks Acquisitions	17/04	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
North American Morning Briefing : Stock Futures -2-	11/04	DJ
Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call	10/04
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	09/04	MT
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding	08/04	CI
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	08/04	CI
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding	02/04	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer	17/02	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	17/02	CI
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02	CI
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	31/01	CI
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	17/01	CI
Windtree Therapeutics, Inc. Announces Reduction in Arrythmias in a New Study With Istaroxime And A Pure SERCA2a Activator	03/01	CI
Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	18/12	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer	29/23/29	CI
Windtree Therapeutics Secures US Patent Covering Product Candidates Aimed to Treat Heart Failure Patients	23/23/23	MT
Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators	16/23/16	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Certain Stock Options of Windtree Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2023.	05/23/05	CI
Certain Restricted Stock Units of Windtree Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2023.	05/23/05	CI
Certain Warrants of Windtree Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2023.	05/23/05	CI
Certain Common Stock of Windtree Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2023.	05/23/05	CI

Chart Windtree Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Companyâs portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.

Sector

Biotechnology & Medical Research

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.22 USD

Average target price

18 USD

Spread / Average Target

+459.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WINDTREE THERAPEUTICS, INC.	-74.54%	1.91M
MODERNA, INC.	+21.46%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.42%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.98%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+11.12%	25.88B
MEDPACE HOLDINGS, INC.	+36.08%	12.53B
BIO-TECHNE CORPORATION	-6.70%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.43%	10.65B

Other Biotechnology & Medical Research